A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Arterial Hypertension

In brief

This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with pulmonary arterial hypertension (PAH).

Key facts

Study ID
NCT03924154
Run by
Altavant Sciences GmbH
People needed
3
Starts
2019-08-01
Expected to finish
2020-02-24
Last updated by the study team
2020-03-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.